Rico Audrey, Ninove Laetitia, Maarouf Adil, Boutiere Clémence, Durozard Pierre, Demortiere Sarah, Saba Villarroel Paola Mariela, Amroun Abdennour, Fourié Toscane, de Lamballerie Xavier, Pelletier Jean, Audoin Bertrand
Department of Neurology, Aix-Marseille University, University Hospital of Marseille, Marseille, France.
Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.
Mult Scler J Exp Transl Clin. 2021 Nov 29;7(4):20552173211062142. doi: 10.1177/20552173211062142. eCollection 2021 Oct.
We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing ( = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose ( = 4) was seropositive. Four of seven (57%) patients with B-cell proportion >0% and ≤5% were seropositive. All patients with B-cell proportion >5% ( = 15) were seropositive. In all patients, quantitative ELISA measures after vaccination were correlated with B-cell counts measured before vaccination. In patients receiving rituximab, seropositivity after BNT162b2 mRNA vaccination emerged only after B-cell repopulation.
我们研究了接受利妥昔单抗延长间隔给药治疗的复发缓解型多发性硬化症（RRMS）患者在第二次接种BNT162b2 mRNA疫苗四周后的血清学反应（n = 26）。四周时，73%的患者血清学呈阳性。首次接种时无B细胞的患者（n = 4）均无血清学阳性。7例B细胞比例>0%且≤5%的患者中有4例（57%）血清学呈阳性。所有B细胞比例>5%的患者（n = 15）血清学均呈阳性。在所有患者中，接种疫苗后的定量ELISA检测结果与接种前测得的B细胞计数相关。在接受利妥昔单抗治疗的患者中，BNT162b2 mRNA疫苗接种后的血清学阳性仅在B细胞重新增殖后出现。
